Background: The National Free Antiretroviral therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which may cause problems with drug resistance (DR). The number of HIV/AIDS patients in Chengdu ranks first in the national capital city. However, there is little data on the prevalence of HIV-1 DR in this region. Therefore, epidemiological surveillance was conducted on HIV-1 DR among patients receiving ART in Chengdu.
Introduction AIDS, also known as "acquired immunodeficiency syndrome", is a highly malignant infectious disease caused by human immunodeficiency virus (HIV). It has been widely spread around the world, with approximately 36.9 million people living with HIV worldwide at the end of 2017 [1] . The situation of the HIV epidemic is a growing burden to public health in China. As of August 2018, it was reported that 841,478 people were living with HIV/AIDS in China, and the number of deaths was 259,200, ranking first among legal infectious diseases [2] .
Application of highly active antiretroviral therapy (HAART) has significantly reduced the transmission of HIV and has decreased HIV-related morbidity and mortality [3] [4] [5] . In mid-2017, 20.9 million people infected with HIV were receiving antiretroviral therapy globally [1] . China has launched the National Free ART Program in 2002, which has acted as an efficient precaution for HIV. However, as accessibility of ART increases and improves survival rate, it may arouse concerns for drug resistance (DR) [6] [7] [8] [9] . HIVDR poses a serious threat to the prevention of AIDS because it has the potential to affect the efficacy of the first-line regimen. In addition, drugresistant strains can be transmitted to newly infected individuals and are likely selected as dominant strains. HIVDR surveillance has made it possible to detect DR strains in time, evaluate and adjust treatment regimens, and reduce the transmission of DR strains.
Previous investigations of DR around the world have shown that the prevalence of DR varies from different regions, time period and target populations, and indicated that the overall incidence of treatment-naïve individuals is between 0% to 23% [10] [11] [12] . In the past decade, the proportion of DR in China has remained relatively low, at 3.8% in 2004 and 2005, and 3.6% in newly diagnosed HIV-infected people in 2015 [13, 14] . However, these reports are sporadic and limited and still require continuous monitoring to monitor changes in DR and adjust the first-line ART.
Sichuan is a representative province in southwest China and is adjacent to Yunnan and Tibet Autonomous Region. Chengdu is the capital city of Sichuan Province and acts as the political, economic, and cultural center of this area. In 1992, the first By the end of 2016, a total of 18,603 people were living with HIV in Chengdu, which accounts for the largest HIV/AIDs population among other capital cities and 15,633 patients were receiving ART. However, there were little data on the prevalence of HIV-1 DR and drug resistance-associated mutations (DRMs) in this area. Therefore, epidemiological surveillance was conducted on HIV-1 subtypes, DR as well as DRMs profiles among patients receiving ART in Chengdu from 2014 to 2016,, and thus to optimize clinical management, prevention and control of HIV.
Methods
Study design, participants and specimen 6 This study was carried out at the Center for Disease Control and Prevention at Chengdu, Sichuan Province, West China. From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least 6 months were enrolled in this study. The patients who carried resistance gene and were on second-line ART (<6 months) were excluded. Blood samples were collected in EDTA containers, and plasma was extracted and cryopreserved for analyses. Patients who provided written informed consent participated in the study. Demographic, behavioral information and medical history were recorded using a standard questionnaire.
Immune cells count and HIV-1 viral loads assay
To assess immune response, CD4 + T cells count was measured by flow cytometer BD 
Results
Demographic characteristics of study participants and the prevalence of HIV-1 subtypes Between 2014 and 2016, a total of 13,872 HIV-infected patients were tested for HIV-1 VL. 4.7% (653/13872) of cases, whose VL≥1000 copies/ml were considered treatment failure. A total of 481 (481/653) samples were amplified and sequenced successfully for subtypes and genetic resistance. Most of the subjects were male (411/481, 85.4%) and the main route of infection was heterosexual contact (342/481, 71.1%). The median age was 41 years (range: 15-81years), of which 8 50.3% were married. The demographic and subtypes distributions of 481 patients were presented in Table 1 . Based on the generated sequences, six subtypes were identified. CRF01 _AE (261/481, 54.3%) and CRF07_BC (200/481, 41.6%) were found to be the predominant subtypes. Other subtypes such as CRF08_BC (9/481, 1.9%), B (6/481, 1.2%), C (3/481, 0.6%) and CRF55_01B (2/481, 0.4) were found in small proportions.
Prevalence and risk factors of drug resistance
According to the HIV DR Database, 245 DR cases were identified in 481 viral sequences. The overall prevalence of DR in 2014 to 2016 was 1.8% (245/13700, excluding sequencing failures). The comparison of characteristics between patients with and without HIV DR was listed in Table 2 Univariate analyses were conducted to correlate demographic characteristics with drug resistance. No differences were found between the prevalence of DR and gender, age at diagnosis, marriage status, infection routes, treatment duration, treatment change and VL (all p>0.05). CD4 + T cells count (≤200), CRF01_AE and "TDF + 3TC + EFV / NVP / other" are associated with DR (p<0.00). A logistic regression analysis showed there was no factor significantly associated with HIVDR.
Categories of antiretroviral drugs and susceptibility of drug resistance 9 In total, 1.2% of the samples were resistant to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs) and 0.14% to protease inhibitors (PIs). The NRTI-associated mutations were forecasted to be highly resistant to Lamivudine (3TC, 67.8%, 146/245) and Abacavir (ABC, 40.4%, 99/245); resistant to Stavudine (D4T, 50.2%, 123/245), Tenofovir (TDF, 47.76%, 117/245); moderate-or low resistant to Azidothymidine (AZT, 7.3%, 18/245). 96.33% of the patients were predicted to have high resistance to Efavirenz (EFV) and Nevirapine (NVP), followed In our study, M184I/V (59.59%) was the most prevalent mutation associated with NRTIs resistance in our study and was also frequently found in Europe, Africa and other regions in China [35, 36] . It alone causes high resistance to 3TC and FTC, low resistance to ABC and potential resistance to DDI. K 65R is one of the mutations with broad-spectrum resistance, and was found in more than one-quarter of the cases. Nine mutations associated with DR were observed in large proportions and resistant to many NNRTIs. K101 E / H / P, Y181 C / V, and G190 A / E / K / Q / S / V are broad spectrum general mutations resistant to all NNRTIs. The L100I and M230L 13 mutations (4.08%) had low incidence and moderate or High resistance to RPV and ETR but no resistance to the first-line drugs EFV and NVP. These two mutations were found in CRF_01AE, CRF_07BC and subtype C, and patients with these two mutations were undergoing 3TC+TDF+EFV/NVP, indicating that this regimen may be related to these mutations. Three primary mutations M46I, I47A and I50V resistant to PIs were detected in one patient, whose regimen was 3TC+AZT+NVP then switched to LPV/r + 3TC+TDF. This patient showed decreased treatment adherence, and thus resulted in reduced effectiveness of treatment, indicating that clinicians should pay attention to compliance education to avoid similar cases and the transmitting of Drug types and their susceptibility of resistance level. Numbers of patients with TDR by NRTI
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